Altered expression of TIM‐3, LAG‐3, IDO, PD‐L1, and CTLA‐4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients
Journal of Oral Pathology and Medicine2019Vol. 48(8), pp. 669–676
Citations Over TimeTop 12% of 2019 papers
Abstract
It suggests that these immune checkpoint receptors and IDO could be considered as biomarkers to reflect immune status in the tumor microenvironment during nimotuzumab therapy. Blockade of these immune checkpoint receptors might enhance nimotuzumab-based cancer immunotherapy, thus potentially improving clinical outcomes of OSCC patients.
Related Papers
- → Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma(2014)4,353 cited
- → Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy(2010)243 cited
- → Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies(2017)93 cited
- → A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors(2023)13 cited
- → CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma(2021)